Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 16/20 | 0.66 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.66 |
| ▸ | TMPRSS4 | Q9NRS4 | 11/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.61 |
| ▸ | CHUK | O15111 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MYLK | Q15746 | 1/20 | 0.61 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464212 | 0.93 | P2RX1 (0.60) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL5469870 | 0.89 | TMPRSS4 (0.69) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL5464092 | 0.81 | TOP1 (0.46) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL5470386 | 0.81 | TRPV1 (0.59) | TMPRSS4MEN1KMT2A | |
| SCHEMBL5468426 | 0.80 | TMPRSS4 (0.65) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL130439 | 0.80 | P2RX1 (0.81) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL127962 | 0.80 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL5464214 | 0.79 | TMPRSS4 (0.65) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL23303456 | 0.78 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL132386 | 0.77 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | P2RX1 4478/4885P2RX7 4702/4885P2RX4 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.